Bernstein on Alnylam Pharmaceuticals (ALNY): 'A Strident but Unconvincing Bear Case'
Tweet Send to a Friend
Bernstein SocGen Group analyst William Pickering reiterated an Outperform rating and $305.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
